Omeprazole, one of the most widely used proton pump inhibitors (PPIs), has a complicated relationship with calcium that does not follow the straightforward logic most people assume. The common worry is that suppressing stomach acid prevents your body from absorbing calcium, but controlled studies have challenged that idea. The real concern is broader: long-term omeprazole use is associated with increased fracture risk through pathways that may go well beyond absorption alone.
Does Omeprazole Actually Block Calcium Absorption?
The intuitive story sounds convincing. Stomach acid helps dissolve calcium, especially calcium carbonate, so dialing acid production down to nearly nothing should mean less calcium gets into your bloodstream. For years, that reasoning was treated as established fact in many clinical settings. But when researchers directly measured fractional calcium absorption in people taking omeprazole daily for about 30 days, the expected drop did not materialize. Calcium absorption averaged around 20% at baseline and roughly 23% after a month of omeprazole, with no statistically significant change. Neither gastric pH, blood levels of omeprazole, nor how faithfully participants took the drug predicted any shift in absorption. The only factor that correlated with changes in absorption was the participant’s active vitamin D level at baseline.
1PubMed Central. Do Proton Pump Inhibitors Decrease Calcium Absorption?That result is counterintuitive, but it has a plausible explanation. Calcium absorption in the gut happens through two routes. One is passive, driven by the concentration of dissolved calcium in the intestinal fluid. The other is active, controlled by vitamin D signaling in cells lining the small intestine. At normal dietary calcium loads, the active pathway contributes meaningfully, and that pathway does not depend on stomach acid at all. So even if a slightly lower gastric pH made some calcium salts dissolve less efficiently, the active vitamin D-mediated transport may compensate, at least over typical supplement doses and short time frames.
This does not close the case. The study measured absorption over about a month. Most of the fracture signal in epidemiological data appears after years of continuous PPI use. A short-term study showing stable absorption does not rule out subtle long-term effects, and the fracture data clearly suggest something is going wrong in long-term users.
The Fracture Risk With Long-Term Use
Multiple large observational studies have found that people who use PPIs for a year or longer face a meaningfully higher chance of breaking a hip or spine. One large case-control study found that more than a year of PPI therapy was associated with roughly a 44% increase in hip fracture risk. At the highest doses over the longest durations, the odds more than doubled. The association also showed a dose-response pattern: the longer someone stayed on a PPI, the higher the fracture risk climbed, from about a 22% increase at one year to nearly 60% at four years.
2JAMA. Long-term Proton Pump Inhibitor Therapy and Risk of Hip FractureA prospective cohort study of women found a similar pattern: regular PPI use for at least two years was associated with about a 36% higher risk of hip fracture, and longer use drove the number higher. Adjusting for calcium intake, physical activity, body weight, and other bone health factors did not change the result in any meaningful way, which suggests the association is not simply explained by PPI users being sicker or less active to begin with.
3BMJ. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort studyThese numbers come from observational data, so they cannot prove omeprazole directly causes fractures. It is possible that people who need long-term acid suppression are inherently more prone to fractures for other reasons researchers have not fully captured. But the consistency of the signal across studies, its dose-response pattern, and its persistence after adjusting for known confounders are enough that the FDA added a fracture warning to PPI labels in 2010, advising prescribers to use the lowest effective dose for the shortest necessary duration.
4PubMed. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System’s analytic toolsIf Not Absorption, Then What?
If calcium absorption does not take the hit researchers originally expected, the fracture signal needs another explanation. Several mechanisms have been proposed, and the honest answer is that more than one may contribute simultaneously.
Direct Effects on Bone Cells
Bone is constantly being remodeled by two types of cells: osteoclasts, which break bone down, and osteoblasts, which build it back up. Lab studies have shown that PPIs can inhibit both cell types. At higher concentrations, PPIs reduced the ability of osteoclasts to resorb bone and also reduced the ability of osteoblasts to form new mineralized tissue. The net result could be lower overall bone turnover, which sounds benign but in practice means damaged bone may not be replaced as effectively.
5PubMed. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activityThere is an important caveat. Osteoclasts use a proton pump to dissolve bone, and omeprazole can theoretically inhibit that pump. But early research showed that omeprazole was far more potent against the stomach’s acid pump than against the one in bone cells. The concentration needed to inhibit osteoclast-driven calcium release from bone was roughly 800 times higher than the concentration needed to suppress stomach acid.
6Biochimica et Biophysica Acta (BBA) – Biomembranes. Omeprazole and bafilomycin, two proton pump inhibitors: Differentiation of their effects on gastric, kidney and bone H+-translocating ATPases Whether clinically relevant concentrations accumulate in bone tissue during years of daily use remains an open question.
The Magnesium Connection
One of the more intriguing indirect pathways runs through magnesium. Long-term PPI use can cause low magnesium levels by altering the way the intestine absorbs it. The proposed mechanism involves a pH change in the intestinal lumen that affects a specific magnesium transport channel.
7Endocrine Abstracts. Omeprazole induced hypomagnesemia leading to hypocalcemia When magnesium drops, parathyroid hormone (PTH) secretion becomes impaired, and without adequate PTH signaling, calcium levels in the blood can fall too. PPI-related low magnesium has been reported to trigger a cascade of electrolyte problems including low calcium, low potassium, and low phosphate.
8PubMed Central. Multiple electrolyte disorders triggered by proton pump inhibitor-induced hypomagnesemia: Case reports with a mini-review of the literatureThis does not happen to everyone on a PPI, and severe cases are uncommon enough to show up mostly as case reports and small series. But for someone who is already borderline low in magnesium because of diet, age, or another medication, omeprazole could be the tipping point.
Gastrin and Parathyroid Hormone
When omeprazole suppresses acid, the stomach responds by pumping out more gastrin, a hormone that normally stimulates acid production. Elevated gastrin may independently stimulate the parathyroid glands to release more PTH. Animal studies have shown that sustained gastrin infusion increased parathyroid gland size and reduced bone density. However, the evidence for this mechanism in humans is mixed. One large observational study found that PPI users who were not taking calcium supplements did not show a significant increase in hyperparathyroidism, which does not support the gastrin theory as a universal explanation.
9PubMed Central. The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture—results of a large observational cohort studyBone Density Versus Fracture Risk
One of the stranger aspects of this topic is that PPI use does not reliably show up as lower bone mineral density on DEXA scans. A longitudinal study found no significant decrease in bone density at either the hip or the spine that could be attributed to PPI use.
10Gastroenterology. Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss This is puzzling. If bone density is not dropping but fractures are increasing, it suggests PPIs may affect bone quality rather than bone quantity, or that the fracture signal in epidemiological studies partially reflects confounding factors that researchers have not fully disentangled.
Bone strength depends on more than just how much mineral is packed into a given area. The microarchitecture of bone tissue, the collagen matrix, and how well the remodeling cycle repairs fatigue damage all matter. It is plausible that PPIs affect one of these subtler dimensions in a way that does not show up on a standard density scan but increases the odds of fracturing under stress. This remains speculative, but it explains why the fracture-risk data and the bone-density data seem to tell different stories.
PPIs Versus H2 Blockers
If you are worried about bones and need acid suppression, the natural question is whether a less potent acid blocker is safer. H2 receptor antagonists, such as famotidine, suppress acid less aggressively than omeprazole. A meta-analysis comparing the two classes found that PPIs were significantly associated with an increased risk of spine fractures, while H2 blockers were not. The same pattern held for hip fractures: PPIs showed a significant increase, but the risk with H2 blockers did not reach significance.
11PubMed. Meta-analysis: risk of fractures with acid-suppressing medicationA large Korean study directly comparing the two found that regular PPI users in the previous year had about a 37% higher risk of osteoporotic fracture compared to patients who used only H2 blockers.
12PubMed Central. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease That does not mean H2 blockers are entirely benign for bone, but the signal is notably weaker. For people with mild reflux who do not truly need the stronger acid suppression a PPI provides, stepping down to an H2 blocker is a reasonable conversation to have with a physician.
How Omeprazole May Undermine Osteoporosis Treatment
For people already diagnosed with osteoporosis, the interaction between omeprazole and bisphosphonate drugs such as alendronate adds another layer of concern. Bisphosphonates are the backbone of osteoporosis treatment, and they need to be absorbed through the GI tract. A large observational analysis found that alendronate reduced hip fracture risk by about 39% in patients who were not using a PPI. In patients who were simultaneously taking a PPI, that benefit shrank to a non-significant 19% reduction. The erosion of benefit depended on cumulative PPI exposure: low cumulative doses had little impact, but patients exposed to more than about a year’s worth of cumulative PPI doses showed no significant hip fracture reduction from alendronate at all.
13JAMA Internal Medicine. Proton Pump Inhibitor Use and the Antifracture Efficacy of AlendronateA meta-analysis looking at the combined use of bisphosphonates and PPIs confirmed an overall increase in fracture risk compared to bisphosphonates alone, with spine fractures being particularly affected.
14PubMed Central. Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis If you are taking a bisphosphonate for osteoporosis and also taking omeprazole, your bone treatment may be working less well than expected. This is a situation worth flagging with the prescribing physician, because the two medications are commonly prescribed together, especially in older adults who have both acid reflux and thinning bones.
Does Your Genetics Change the Risk?
Omeprazole is broken down in the liver primarily by an enzyme called CYP2C19. People carry different genetic variants of this enzyme, which affect how quickly they metabolize the drug. “Poor metabolizers” clear omeprazole more slowly, so the drug effectively lingers longer and suppresses acid more completely. The logical expectation is that poor metabolizers would face greater bone risk from the same dose.
A hospital-based study of over 1,500 long-term PPI users tested this hypothesis by comparing fracture rates and bone density across different CYP2C19 metabolizer groups. Poor metabolizers did show numerically lower bone density at the spine and hips compared to other groups. However, the difference was not statistically significant, and fracture rates did not differ across metabolizer types either.
15PubMed Central. CYP2C19 genotypes and osteoporotic fractures in long‐term users of proton pump inhibitors: A hospital‐based study The study was not enormous, and the trend toward lower bone density in poor metabolizers is the kind of signal that a larger study might confirm. For now, pharmacogenomic testing is not recommended as a way to guide bone-health decisions in PPI users, but it is a thread researchers continue to pull.
What Long-Term Users Should Actually Do
Given all these moving parts, the practical guidance from gastroenterology professional societies is more measured than you might expect. The American Gastroenterological Association’s expert review advises that long-term PPI users should not routinely increase their calcium, vitamin B12, or magnesium intake beyond the standard recommended daily allowance. It also recommends against routine screening of bone mineral density, serum magnesium, or other lab markers solely because of PPI use.
16PubMed. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological AssociationThat guidance applies to the average user without additional risk factors. The picture shifts for people who already have reasons to worry about their bones. A 2024 review in a leading gastroenterology journal offers a more stratified approach: for PPI users without other osteoporosis risk factors, the estimated bone-related risk is small, on the order of 0.1% to 0.5% per patient-year, and standard age-based osteoporosis screening plus recommended daily calcium and vitamin D is enough. For PPI users who do have risk factors, such as advanced age, low body weight, smoking, steroid use, or a family history of osteoporotic fracture, a baseline bone density assessment and proactive supplementation become more appropriate.
17Gastroenterology. Long-Term Proton Pump Inhibitor Use: Review of Indications and Special ConsiderationsThe overriding principle is that omeprazole should be used at the lowest effective dose for as long as it is genuinely needed, and not longer. Many people end up on a PPI after an acute episode and never revisit whether they still need it. A periodic reassessment, trying a lower dose or stepping down to an H2 blocker, is the single most impactful thing most users can do for their bone health.
Calcium Carbonate Versus Calcium Citrate on a PPI
One piece of practical advice that has circulated for years is that people on omeprazole should switch from calcium carbonate supplements to calcium citrate, on the theory that calcium citrate does not need stomach acid to dissolve. The logic is appealing, and calcium citrate is indeed more soluble in a low-acid environment. But the direct absorption study discussed earlier did not find that omeprazole impaired fractional calcium absorption in the first place, which weakens the premise for the switch.
18PubMed Central. Do Proton Pump Inhibitors Decrease Calcium Absorption?That said, taking calcium with food is generally recommended regardless of whether you use a PPI. Food stimulates whatever acid production remains, slows gastric emptying, and provides other nutrients that support calcium uptake. If you are on omeprazole and prefer calcium carbonate for cost or convenience, taking it with a meal is a sensible habit. Calcium citrate is a reasonable alternative if you tend to take supplements on an empty stomach, but the evidence does not support treating the switch as medically urgent for PPI users specifically.
Fall Risk and Confounding Factors
A dimension of the fracture question that rarely gets enough attention is whether PPIs contribute to falls rather than, or in addition to, weaker bones. PPIs can lower magnesium, as discussed, and severe magnesium depletion causes muscle weakness, dizziness, and unsteadiness. Fractures require both a weakened bone and a force applied to it, and in older adults that force almost always comes from a fall. If omeprazole increases fall risk even slightly through electrolyte derangements or through other systemic effects researchers have not fully characterized, that alone could inflate fracture rates without any change in bone density.
Observational fracture studies adjust for many confounders but rarely capture fall frequency directly. This is one reason the epidemiological signal is strong and persistent but the mechanistic explanation remains incomplete. The fracture risk is real enough to take seriously and guide clinical decisions, but anyone who tells you the precise biological pathway is settled is getting ahead of the evidence.